Soleno Therapeutics Inc [NASDAQ: SLNO] plunged by -$8.17 during the normal trading session on Thursday and reaching a high of $88.36 during the day while it closed the day at $80.32.
Soleno Therapeutics Inc stock has also loss -6.83% of its value over the past 7 days. However, SLNO stock has inclined by 36.04% in the 3 months of the year. Over the past six months meanwhile, it has gained 74.99% and gained 89.39% year-on date.
The market cap for SLNO stock reached $4.05 billion, with 48.53 million shares outstanding and 41.76 million shares in the current float. Compared to the average trading volume of 915.62K shares, SLNO reached a trading volume of 5642642 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Soleno Therapeutics Inc [SLNO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SLNO shares is $113.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SLNO stock is a recommendation set at 1.11. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for Soleno Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 23, 2025. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on March 05, 2025, representing the official price target for Soleno Therapeutics Inc stock. Previously, the target price had yet another raise to $74, while Stifel analysts kept a Buy rating on SLNO stock.
The Price to Book ratio for the last quarter was 16.78, with the Price to Cash per share for the same quarter was set at 5.75.
SLNO stock trade performance evaluation
Soleno Therapeutics Inc [SLNO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.83. With this latest performance, SLNO shares gained by 3.33% in over the last four-week period, additionally plugging by 74.99% over the last 6 months – not to mention a rise of 78.69% in the past year of trading.
Soleno Therapeutics Inc [SLNO]: An insightful look at the core fundamentals
Return on Equity for this stock declined to -81.42%, with Return on Assets sitting at -81.42%.
Soleno Therapeutics Inc [SLNO]: Institutional Ownership
There are presently around $112.43%, or 114.60% of SLNO stock, in the hands of institutional investors. The top three institutional holders of SLNO stocks are: VIVO CAPITAL, LLC with ownership of 7.32 million shares, which is approximately 18.9401%. CARLYLE GROUP INC., holding 4.07 million shares of the stock with an approximate value of $$166.36 million in SLNO stocks shares; and CARLYLE GROUP INC., currently with $$137.14 million in SLNO stock with ownership which is approximately 8.6946%.
